Free Trial

Haemonetics (HAE) Stock Price, News & Analysis

Haemonetics logo
$74.58 -2.08 (-2.71%)
Closing price 03:59 PM Eastern
Extended Trading
$74.62 +0.04 (+0.05%)
As of 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Haemonetics Stock (NYSE:HAE)

Key Stats

Today's Range
$74.58
$76.83
50-Day Range
$63.64
$78.35
52-Week Range
$55.30
$94.99
Volume
451,218 shs
Average Volume
674,721 shs
Market Capitalization
$3.58 billion
P/E Ratio
22.53
Dividend Yield
N/A
Price Target
$97.30
Consensus Rating
Buy

Company Overview

Haemonetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
98th Percentile Overall Score

HAE MarketRank™: 

Haemonetics scored higher than 98% of companies evaluated by MarketBeat, and ranked 27th out of 903 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Haemonetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Haemonetics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Haemonetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Haemonetics are expected to grow by 10.77% in the coming year, from $4.55 to $5.04 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Haemonetics is 22.66, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.63.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Haemonetics is 22.66, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.67.

  • Price to Earnings Growth Ratio

    Haemonetics has a PEG Ratio of 1.22. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Haemonetics has a P/B Ratio of 4.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Haemonetics' valuation and earnings.
  • Percentage of Shares Shorted

    7.73% of the float of Haemonetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Haemonetics has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in Haemonetics has recently decreased by 9.85%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Haemonetics does not currently pay a dividend.

  • Dividend Growth

    Haemonetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.73% of the float of Haemonetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Haemonetics has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in Haemonetics has recently decreased by 9.85%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Haemonetics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 22 news articles for Haemonetics this week, compared to 7 articles on an average week.
  • Search Interest

    Only 1 people have searched for HAE on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Haemonetics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.84% of the stock of Haemonetics is held by insiders.

  • Percentage Held by Institutions

    99.67% of the stock of Haemonetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Haemonetics' insider trading history.
Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

HAE Stock News Headlines

Barrington Research Expects Weaker Earnings for Haemonetics
Haemonetics' (HAE) Outperform Rating Reiterated at Barrington Research
"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
Haemonetics (NYSE:HAE) Upgraded to "Buy" at Citigroup
Zacks Research Forecasts Stronger Earnings for Haemonetics
Citigroup Upgrades Haemonetics (HAE)
See More Headlines

HAE Stock Analysis - Frequently Asked Questions

Haemonetics' stock was trading at $78.08 at the start of the year. Since then, HAE shares have decreased by 4.0% and is now trading at $74.96.

Haemonetics Corporation (NYSE:HAE) announced its quarterly earnings data on Thursday, May, 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.02. The business's revenue for the quarter was down 3.5% on a year-over-year basis.
Read the conference call transcript
.

Haemonetics' top institutional shareholders include Confluence Investment Management LLC (0.08%), Harbor Capital Advisors Inc. (0.06%), Cardinal Capital Management (0.04%) and Central Pacific Bank Trust Division (0.02%). Insiders that own company stock include Michelle L Basil, Anila Lingamneni, Josep Llorens, Stewart W Strong and Laurie A Miller.
View institutional ownership trends
.

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Haemonetics investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/08/2025
Today
7/15/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Health Care Supplies
Current Symbol
NYSE:HAE
CIK
313143
Employees
3,023
Year Founded
1971

Price Target and Rating

High Price Target
$116.00
Low Price Target
$68.00
Potential Upside/Downside
+27.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.31
Trailing P/E Ratio
23.14
Forward P/E Ratio
16.83
P/E Growth
1.22
Net Income
$167.68 million
Net Margins
12.32%
Pretax Margin
15.58%
Return on Equity
26.37%
Return on Assets
9.22%

Debt

Debt-to-Equity Ratio
1.12
Current Ratio
1.62
Quick Ratio
0.99

Sales & Book Value

Annual Sales
$1.36 billion
Price / Sales
2.70
Cash Flow
$7.31 per share
Price / Cash Flow
10.48
Book Value
$16.34 per share
Price / Book
4.69

Miscellaneous

Outstanding Shares
48,041,000
Free Float
47,157,000
Market Cap
$3.68 billion
Optionable
Optionable
Beta
0.39

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NYSE:HAE) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners